U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C18H21NO3.2C4H6O6.5H2O
Molecular Weight 988.9786
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCODONE BITARTRATE

SMILES

O.O.O.O.O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]15CCN(C)[C@H](C4)[C@]5([H])CCC2=O.[H][C@@]67OC8=C(OC)C=CC9=C8[C@@]6%10CCN(C)[C@H](C9)[C@]%10([H])CCC7=O

InChI

InChIKey=JMBRWJAVUIITGV-LNNMZZBZSA-N
InChI=1S/2C18H21NO3.2C4H6O6.5H2O/c2*1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;2*5-1(3(7)8)2(6)4(9)10;;;;;/h2*3,6,11-12,17H,4-5,7-9H2,1-2H3;2*1-2,5-6H,(H,7,8)(H,9,10);5*1H2/t2*11-,12+,17-,18-;2*1-,2-;;;;;/m0011...../s1

HIDE SMILES / InChI
Molecular Formula C18H21NO3
Molecular Weight 299.3642
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Benzhydrocodone is a prodrug of hydrocodone. Benzhydrocodone is formed by covalently bonding hydrocodone to benzoic acid. Benzhydrocodone itself is not pharmacologically active, but must be metabolized to hydrocodone by enzymes in the intestinal tract to optimally deliver its pharmacologic effects. Hydrocodone is a full agonist of the opioid receptors with a higher affinity for the mu-opioid receptor. Upon binding, hydrocodone produces an analgesic effect with no ceiling. APADAZ a combination of benzhydrocodone and acetaminophen is FDA approved and indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. APADAZ, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death.

CNS Activity

Approval Year

1943
64
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
ZOHYDRO ER

Approved Use

ZOHYDRO ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Launch Date

1.38257275E12
Primary
Approved
8307
APADAZ

Approved Use

APADAZ is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen, and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Launch Date

1.54647357E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27138027/
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23.6 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/005213s039lbl.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
155 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27138027/
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27138027/
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/005213s039lbl.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
55%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/005213s039lbl.pdf
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg multiple, oral (total)
Overdose
Dose: 30 mg
Route: oral
Route: multiple
Dose: 30 mg
Co-administed with::
clarithromycin
valproic acid(250 mg, 2 times per day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
unhealthy, 5 years
n = 1
Health Status: unhealthy
Condition: cold
Age Group: 5 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
Other AEs: Adverse event...
Other AEs:
Adverse event (grade 5)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Other AEs: Electrocardiogram QTc interval prolonged...
Other AEs:
Electrocardiogram QTc interval prolonged
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Other AEs: Respiratory depression, Addiction...
Other AEs:
Respiratory depression (grade 5)
Addiction
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (1%)
Nausea (1%)
Headache (1%)
Dizziness (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
AEs

AEs

AESignificanceDosePopulation
Adverse event grade 5
30 mg multiple, oral (total)
Overdose
Dose: 30 mg
Route: oral
Route: multiple
Dose: 30 mg
Co-administed with::
clarithromycin
valproic acid(250 mg, 2 times per day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
unhealthy, 5 years
n = 1
Health Status: unhealthy
Condition: cold
Age Group: 5 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/20837591
Electrocardiogram QTc interval prolonged
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Withdrawal syndrome neonatal
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Addiction
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Respiratory depression grade 5
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf
Dizziness 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Headache 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Nausea 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Vomiting 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf
Page: p. 115
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670
substrate
1168
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2B6
648

CYP2C19
955
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2B6
648
 minor
CYP2C19
955
 minor
CYP2D6
1168
 yes
yes (co-administration study)
Comment: The 90% confidence interval (CI) of the geometric means for hydrocodone AUCinf (98 to 115%), AUCt (98 to 115%), and Cmax (93 to 121%) values were within the range of 80 to 125% when a single dose of HYSINGLA ER 20 mg was co-administered with CYP2D6 inhibitor paroxetine
CYP3A4
1670
 yes
yes (co-administration study)
Comment: Co-administration of HYSINGLA ER and CYP3A4 inhibitor ketoconazole increased mean hydrocodone AUC and Cmax by 135% and 78%, respectively;
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5779
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5779
ZINC
ZINC000001280665
http://zinc15.docking.org/substances/ZINC000001280665
eMolecules
29539213
https://www.emolecules.com/cgi-bin/more?vid=29539213
PubMed

PubMed

TitleDatePubMed
Effect of narcotic pain reliever on pulp tests in women.
2002 Jul
Gateways to clinical trials.
2002 Jul-Aug
A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery.
2002 Jun
[Trends in the incidence of hepatic tumors in childhood].
2002 Mar-Apr
Exacerbation of panic disorder symptoms following Vicodin exposure.
2002 Nov-Dec
Rational use of analgesic combinations.
2002 Oct
A field evaluation of five on-site drug-testing devices.
2002 Oct
Detection of cocaine analytes and opiates in nails from postmortem cases.
2002 Oct
Surveillance of drug identification calls: an overlooked poison center responsibility.
2002 Oct
Effect of gastrointestinal bleeding and oral medications on acquisition of vancomycin-resistant Enterococcus faecium in hospitalized patients.
2002 Oct 15
Senate committee fights hydrocodone abuse.
2002 Sep
[Hypoxic brain damage in victims of fatal road traffic accident: prevalence, distribution and association with survival time and other head and extracranial injuries].
2002 Sep
Review of the analgesic efficacy of ibuprofen.
2003 Apr
The synergistic analgesic interactions between hydrocodone and ibuprofen.
2003 Dec
Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
2003 Jan
Hair analysis for opiates: evaluation of washing and incubation procedures.
2003 Jun 5
Rapid communication: laparoscopic Anderson-Hynes dismembered pyeloplasty using the da Vinci robot: technical considerations.
2003 Mar
Cognitive and motor function after administration of hydrocodone bitartrate plus ibuprofen, ibuprofen alone, or placebo in healthy subjects with exercise-induced muscle damage: a randomized, repeated-dose, placebo-controlled study.
2003 Mar
Current concepts in acute pain management.
2003 May
Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study.
2003 Nov
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.
2003 Nov-Dec
Carisoprodol withdrawal syndrome.
2004 Dec
A message of hope.
2004 Fall
Refractory status epilepticus.
2004 Feb
Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor.
2004 Feb
Postoperative pain management after anterior cruciate ligament reconstruction.
2004 Jan
Loss prevention case of the month. Monitoring remains critical.
2004 Jan
Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone.
2004 Jan-Feb
Dose-response relationship between opioid use and adverse effects after ambulatory surgery.
2004 Jul
Efficacy of ibuprofen-hydrocodone for the treatment of postoperative pain after periodontal surgery.
2004 Jun
Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents.
2004 Jun
Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000.
2004 Jun
Hallucinations with zolpidem and fluoxetine in an impaired driver.
2004 Mar
CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
2004 Mar
Topical metronidazole (10 percent) decreases posthemorrhoidectomy pain and improves healing.
2004 May
[Origin and growth of the National Program of Continuous Academic Development for the General Physician].
2004 May-Jun
Local anesthetic infusion pumps improve postoperative pain after inguinal hernia repair: a randomized trial.
2004 Nov
6-oxo-morphinane oximes: pharmacology, chemistry and analytical application.
2004 Oct
Continuous local anesthetic infusion for pain management after outpatient inguinal herniorrhaphy.
2004 Oct
Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects.
2004 Oct
Fracture of an endoluminal nitinol stent used in the treatment of tracheal collapse in a dog.
2004 Oct 15
Metaxalone (Skelaxin)-related death.
2004 Sep
Cough suppression during flexible bronchoscopy using combined sedation with midazolam and hydrocodone: a randomised, double blind, placebo controlled trial.
2004 Sep
Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs.
2005 Apr 8
Detection of hypoventilation during thoracoscopy: combined cutaneous carbon dioxide tension and oximetry monitoring with a new digital sensor.
2005 Feb
A preclinical comparison between different opioids: antinociceptive versus adverse effects.
2005 Feb
The GC-MS detection and characterization of neopine resulting from opium use and codeine metabolism and its potential as an opiate-product-use marker.
2005 Jun
A 46-year-old man with excruciating shoulder pain.
2005 Mar
Oral analgesics for acute nonspecific pain.
2005 Mar 1
Patents

Patents

04272541
12
07321038
10
08491935
42
08569329
42
JP2000501709A
75
JP2005506351A
26
JP2010163446A
20
JP2010509227A
64
JP2011511782A
10
JP2011520977A
49
JP2013241461A
10
JP4806507B2
10

Sample Use Guides

In Vivo Use Guide
APADAZ Immediate-release tablets: 6.12 mg benzhydrocodone (equivalent to 6.67 mg benzhydrocodone hydrochloride) and 325 mg acetaminophen. Initiate treatment with APADAZ at 1 or 2 tablets every 4 to 6 hours as needed for pain. Dosage should not exceed 12 tablets in a 24­ hour period.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 17 21:10:18 UTC 2022
Edited
by admin
on Sat Dec 17 21:10:18 UTC 2022
Record UNII
NO70W886KK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCODONE BITARTRATE
ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
HYDROCODONE BITARTRATE COMPONENT OF ALLAY
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF TUSSIGON
Common Name English
HYDROCODONE TARTRATE
MART.  
Common Name English
CODAMINE COMPONENT HYDROCODONE BITARTRATE
Common Name English
TUSSIGON COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYSINGLA
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF ANEXSIA
Common Name English
NORCO COMPONENT HYDROCODONE BITARTRATE
Common Name English
ZUTRIPRO COMPONENT HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE BITARTRATE [USAN]
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF LORCET-HD
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF REZIRA
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF VICODIN
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF REPREXAIN
Common Name English
DURADYNE DHC COMPONENT HYDROCODONE BITARTRATE
Common Name English
REPREXAIN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE [ORANGE BOOK]
Common Name English
DIHYDROCODEINONE BITARTRATE HYDRATE
Common Name English
OBREDON COMPONENT HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE BITARTRATE [USP MONOGRAPH]
Common Name English
NORCET COMPONENT HYDROCODONE BITARTRATE
Common Name English
LORCET-HD COMPONENT HYDROCODONE BITARTRATE
Common Name English
DICODID
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF HYCODAN
Common Name English
HYDROCODONE BITARTRATE CII
USP-RS  
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF FLOWTUSS
Brand Name English
VICODIN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE [VANDF]
Common Name English
AZDONE COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF OBREDON
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF VICOPRIN
Common Name English
ALLAY COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYCODAN
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF ZYDONE
Common Name English
HY-PHEN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF NORCET
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF LORTAB
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF HY-PHEN
Common Name English
HYDROCODONE TARTRATE [MART.]
Common Name English
MERCODINONE
Brand Name English
HYCOFENIX COMPONENET OF HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE
EP  
Common Name English
Hydrocodone bitartrate [WHO-DD]
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF CODAMINE
Common Name English
REZIRA COMPONENT HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF DURADYNE DHC
Common Name English
4,5?-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5)
Common Name English
VANTRELA
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF HYCOMINE
Common Name English
LORTAB COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF ZUTRIPRO
Brand Name English
HYCOMINE COMPONENT HYDROCODONE BITARTRATE
Common Name English
ZOHYDRO
Brand Name English
HYDROCODONE BITARTRATE HEMIPENTAHYDRATE [MI]
Common Name English
CEP-33237
Code English
HYDROCODONE BITARTRATE COMPONENT OF CO-GESIC
Common Name English
ANEXSIA COMPONENT HYDROCODONE BITARTRATE
Common Name English
TYCOLET COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF HYCOFENIX
Brand Name English
BANCAP HC COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF TYCOLET
Common Name English
VICOPROFEN COMPONENT HYDROCODONE BITARTRATE
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-3-METHOXY-17-METHYL-, (5.ALPHA.)-, (2R,3R))-2,3-DIHYDROXYBUTANEDIOATE (1:1), HYDRATE (2:5)
Common Name English
HYDROPANE COMPONENT HYDROCODONE BITARTRATE
Common Name English
CO-GESIC COMPONENT HYDROCODONE BITARTRATE
Common Name English
ZYDONE COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYCODAN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE CII [USP-RS]
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF NORCO
Common Name English
HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE [EP MONOGRAPH]
Common Name English
HYDROCODONE BITARTRATE HEMIPENTAHYDRATE
MI  
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF HYDROPANE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF VICOPROFEN
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF BANCAP HC
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF AZDONE
Common Name English
FLOWTUSS COMPONENT HYDROCODONE BITARTRATE
Brand Name English
VICOPRIN COMPONENT HYDROCODONE BITARTRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
NCI_THESAURUS C66917
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
DEA NO. 9193
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
NCI_THESAURUS C1506
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
Code System Code Type Description
RS_ITEM_NUM
1315001
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
DRUG BANK
DBSALT001233
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
EVMPD
SUB02559MIG
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
EPA CompTox
DTXSID7091543
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
CAS
34195-34-1
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
PUBCHEM
23724881
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
DAILYMED
NO70W886KK
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
ChEMBL
CHEMBL1457
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
RXCUI
142439
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY RxNorm
FDA UNII
NO70W886KK
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
CHEBI
5780
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
MERCK INDEX
M6093
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY Merck Index
WIKIPEDIA
Hydrocodone bitartrate
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
NCI_THESAURUS
C29099
Created by admin on Sat Dec 17 21:10:19 UTC 2022 , Edited by admin on Sat Dec 17 21:10:19 UTC 2022
PRIMARY
Related Record Type Details
Structure of HYDROCODONE BITARTRATE ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of HYDROCODONE
PARENT -> SALT/SOLVATE
Structure of HYDROCODONE BITARTRATE ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of HYDROCODONE BITARTRATE ANHYDROUS
ANHYDROUS->SOLVATE
Structure of TARTARIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CODEINE ANHYDROUS
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENZOPHENONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYLCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of OXYCODONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of THEBAINE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of HYDROMORPHONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DIHYDROCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of MORPHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CODEINONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of HYDROCODONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966